Site Investigation Articles & Analysis
30 news found
ImmunogenX is pleased to report the successful completion of the CeliacShield trial (NCT03585478), focused on treating celiac disease (CeD) patients, will be published in the premier journal Gastroenterology and is entitled: Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed to a Gluten Challenge doi.org/10.1053/j.gastro.2022.07.071 This ...
Endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and Egnyte, the secure platform for content collaboration and governance, today announced that Endpoint Clinical has partnered with Egnyte, providing a Google Cloud-compliant platform to establish a secure file server that can share IRT audit logs directly with Investigators ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
” About the CONVERT Study CONVERT is a prospective, open-label, multi-center, single-arm study being conducted at up to 20 investigational sites. The study plans to enroll 140 subjects with severe emphysema and collateral ventilation in the target lobe. ...
The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke. ...
Following the successful completion of pilot studies, clinical investigators enrolled 174 patients between the ages of 12 and 21 in the largest single concussion therapy trial known to validate the effectiveness, safety, and tolerability of the system. “As the principal investigator in the study we are thankful for the hard work of the research team from ...
” Zimmetry’s building science professionals provide comprehensive site investigations with indoor environmental quality testing services to improve conditions in all types of buildings throughout Puerto Rico for those suffering from allergic conjunctivitis or from other conditions due to exposure to respiratory allergens, irritants and asthma ...
Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal resection. Up to 20 U.S. and European sites will enroll patients in the study. Tampa General Hospital, Tampa, Fla., under the direction of site Principal Investigator Jorge Marcet, MD, professor of the Department of Surgery and director, Colon ...
BySafeHeal
In a first study, EM Imaging will supply EMI-137, a safe and well-tolerated clinical grade investigational molecular optical imaging agent to two investigational sites to perform clinical efficacy studies in pancreatic and lung cancers. ...
To view the publication, visit: https://www.canjurol.com/html/free-articles/Cdn_JU29_I1_05_FREE_DrGilling.pdf 1Dr. Alexis E. Te was a study site principal investigator for the WATER study and consultant to PROCEPT BioRobotics. ...
“As we initiate the second phase, our team is focused on adding clinical sites across the U.S. and expanding internationally to include several enrolling sites in France. ...
The initial treatment visit will occur at the investigative site and instillation will be performed by a qualified physician. ...
“I am proud of our courageous field team that traveled throughout the pandemic, who along with our R&D colleagues in Israel, collaborated to ensure investigative sites and patients had optimal support during the study’s enrollment ...
Following the successful completion of pilot studies, TecTraum is nearing completion of a large multi-site pivotal clinical trial to validate the effectiveness, safety, and tolerability of the system in patients between the ages of 12 and 21. ...
Biologics Development and Manufacturing Thermo Fisher has recently assumed operational responsibility for a new 1.5-million-square-foot biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with CSL Limited. ...
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ...
The first patients to participate in CV-SQuISH-ED were enrolled by Dr. Tonya Jagneaux, site principal investigator at Our Lady of the Lake Regional Medical Center in Baton Rouge, La. and by Dr. Daniel Henning, a University of Washington emergency medicine physician and site principal investigator at Harborview Medical Center in ...
Mark Einstein, MD, MS, FACS, FACOG, Principal Coordinating Investigator for the REVEAL 1 trial, said, "There is a very significant need for a non-surgical therapeutic for young women suffering from HPV-associated cervical dysplasia. ...
Approximately 4,000 clinical trials are conducted each year in Europe, which is 20% of the global clinical trials market.* These facilities feature innovative and highly automated technologies to optimize efficiency and quality across the pharma services supply chain. The Rheinfelden site opens in late December 2020 and the Weil am Rhein site will open in ...
This grant will support Alume's clinical development of its novel nerve illumination technology in surgery. The Principal Investigators on this grant are Michael Whitney, PhD, Scientific Co-Founder and Vice President of Discovery and Brett Berman, MD, Co-Founder and Chief Medical Officer at Alume. ...